{"schema_version":"secwatch.filing_event.v1","accession":"0001157523-23-000197","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2023-02-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:48.465279+00:00","generated_at":"2026-06-19T23:33:21.568318+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"USANA Q4 net sales $228M (-15% YoY), EPS $0.66 (-36%); FY2023 guidance reiterated","bullets":["Q4 net sales $228M, down 15% YoY; diluted EPS $0.66, down 36% YoY.","FY2022 net sales $999M (-16% YoY), EPS $3.59 (-37%); operating cash flow $104M.","Active customers 490,000, down 13% YoY but up 3% sequentially; key markets stabilized.","FY2023 outlook: net sales $850M-$950M, diluted EPS $2.35-$3.30; wide range on China uncertainty.","Ended with $288M cash, debt-free; $83M share buyback remaining; no Q4 repurchases."],"urls":{"canonical":"https://secwatch.observer/filing/0001157523-23-000197","json":"https://secwatch.observer/filing/0001157523-23-000197.json","markdown":"https://secwatch.observer/filing/0001157523-23-000197.md","text":"https://secwatch.observer/filing/0001157523-23-000197.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/a53305227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T23:33:21.568318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3f650932fb90d9e4c407a75dd9fc05a92bd4160a","claim":"USANA HEALTH SCIENCES INC reported fiscal year 2023 results: revenue $850 million to $950 million, EPS $2.35 to $3.30. Guidance reaffirmed.","evidence_excerpt":"Company reiterates fiscal year 2023 net sales and diluted EPS outlook of $850 million to $950 million and $2.35 to $3.30, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year 2023"},{"label":"Revenue","value":"$850 million to $950 million"},{"label":"EPS","value":"$2.35 to $3.30"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"a10a82cd6680465393b460687296bb5b9527c6b1","claim":"USANA HEALTH SCIENCES INC reported fiscal year ended December 31, 2022 results: revenue $999 million, EPS $3.59. Guidance reaffirmed.","evidence_excerpt":"Fiscal year 2022 net sales were $999 million as compared with $1,186 million during fiscal year 2021. Fiscal year 2022 diluted EPS totaled $3.59 versus $5.73 during fiscal year 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended December 31, 2022"},{"label":"Revenue","value":"$999 million"},{"label":"EPS","value":"$3.59"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e4456645605c78ba2b7832d06f0c8e9b37e610ea","claim":"USANA HEALTH SCIENCES INC reported fourth quarter ended December 31, 2022 results: revenue $228 million, EPS $0.66. Guidance reaffirmed.","evidence_excerpt":"Fourth quarter net sales were $228 million versus $267 million during the prior-year period. Fourth quarter diluted EPS was $0.66 as compared with $1.03 during Q4 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/896264/000115752323000197/0001157523-23-000197-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter ended December 31, 2022"},{"label":"Revenue","value":"$228 million"},{"label":"EPS","value":"$0.66"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}